Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2026 | $70.00 | Market Perform | BMO Capital Markets |
| 6/23/2026 | $80.00 | Outperform | RBC Capital Mkts |
| 5/21/2026 | $69.00 | Sell → Neutral | UBS |
| 4/30/2026 | $65.00 | Buy → Neutral | Goldman |
| 1/15/2026 | $77.00 | Neutral → Sell | UBS |
| 10/13/2025 | $86.00 | Equal Weight | Barclays |
| 10/7/2025 | $83.00 | Buy → Neutral | Citigroup |
| 5/5/2025 | $73.00 | Sell → Neutral | UBS |
MIM Anyware is designed to deliver secure, healthcare system-controlled access to the full portfolio of GE HealthCare’s MIM software solutions through a web browser, regardless of their location. The platform enables simultaneous clinical review and processing of imaging data across departments to enhance clinical collaboration and patient care delivery. GE HealthCare (NASDAQ:GEHC) today announced the introduction of MIM Anyware™, a remote access platform that provides secure, healthcare system-controlled access to imaging data through a web browser without requiring local software installation. By enabling authorized users to access MIM software applications from virtually any locat
More than 1,300 pieces of technology to be added across Catholic Health hospitals and ambulatory locations, expanding access to advanced imaging, diagnostics and specialized care closer to home AI-powered technologies to support scheduling, operations, diagnostics, and monitoring across on-device, departmental and enterprise-level applications 10-year Care Alliance combines technology modernization with service support designed to help improve equipment reliability, operational efficiencies and care consistency across Catholic Health Catholic Health, an integrated health system located on Long Island, NY, and GE HealthCare (NASDAQ:GEHC) announced today a 10-year strategic partners
A novel theranostics study explores imaging- and data-informed approaches to support individualized treatment decisions and expand access to theranostics Collaboration stems from a 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collabor
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
BMO Capital Markets initiated coverage of GE HealthCare with a rating of Market Perform and set a new price target of $70.00
RBC Capital Mkts initiated coverage of GE HealthCare with a rating of Outperform and set a new price target of $80.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $69.00
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
SD - GE HealthCare Technologies Inc. (0001932393) (Filer)
SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s
BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob
GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa
GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutic
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026 payable on August 14, 2026, to all shareholders of record as of July 24, 2026.About GE HealthCare Technologies Inc.GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions,
Revenue growth of 7.4%, including Organic revenue growth* of 2.9% Total orders up 1.1% organically versus 10.3% growth in the year-ago period; book-to-bill of 1.07 times and backlog of $21.8 billion Profitability in the quarter was impacted by a discrete PDx supplier issue that has since been resolved Net income margin of 7.6% and Adjusted earnings before interest and taxes (EBIT) margin* of 13.5%; diluted earnings per share (EPS) of $0.85 and Adjusted EPS* of $0.99 Cash flow from operating activities of $290 million and Free cash flow* of $112 million For the full-year 2026, Company reaffirms topline growth driven by healthy global end market demand; reduces profit and Free